Vir Biotechnology (VIR) Net Income towards Common Stockholders (2018 - 2026)

Vir Biotechnology (VIR) has 9 years of Net Income towards Common Stockholders data on file, last reported at -$125.7 million in Q1 2026.

• For the quarter ending Q1 2026, Net Income towards Common Stockholders fell 3.91% year-over-year to -$125.7 million; the trailing twelve-month figure through Mar 2026 stood at -$442.7 million (up 23.36% YoY), and the FY2025 full-year result was -$438.0 million, up 16.09% from the prior year.
• Net Income towards Common Stockholders eased to -$125.7 million in Q1 2026, from -$42.9 million in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of $518.6 million in Q1 2022 to a low of -$213.7 million in Q3 2024.
• A 5-year average of -$69.7 million and a median of -$116.0 million in 2023 frame the typical range for Net Income towards Common Stockholders.
• Peak annual rise in Net Income towards Common Stockholders reached 407.04% in 2022, while the deepest fall reached 223.75% in 2022.
• Tracing VIR's Net Income towards Common Stockholders over 5 years: stood at -$101.6 million in 2022, then retreated by 14.14% to -$116.0 million in 2023, then gained by 9.82% to -$104.6 million in 2024, then surged by 58.96% to -$42.9 million in 2025, then plunged by 192.84% to -$125.7 million in 2026.
• Business Quant data shows VIR's Net Income towards Common Stockholders at -$125.7 million in Q1 2026, -$42.9 million in Q4 2025, and -$163.1 million in Q3 2025.